Intra Cranial EEG Activity During Dexmedetomidine Sedation
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University Health Network, Toronto.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
University Health Network, Toronto
First received: July 13, 2012
Last updated: July 23, 2012
Last verified: July 2012
Various parts of the brain are sensitive to various anesthetics.We like to study the effect of dexmedetomidine on the different parts of the brain in patients who are coming for DBS electrode removal under sedation.
EEG Effect of Dexmedetomidine on the Cortical and Subcortical Structures
||Observational Model: Cohort
Time Perspective: Prospective
||Intra Cranial EEG Activity During Dexmedetomidine Sedation.Comparing the Effects of Dexmedetomidine on the Cortical and the Sub Cortical(Hippocampus) Structures.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||May 2014 (Final data collection date for primary outcome measure)
Cortical and sub cortical structures will have different sensitivities to various anesthetics.The objective of this study is to look at the changes in the intracranial electroencephalographic (EEG) characteristics during dexmedetomidine sedation and to determine the differences in the EEG characteristics between cortical and subcortical structures.
|Ages Eligible for Study:
||18 Years to 80 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation
- Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation
- Lack of informed consent
- Hypersensitivity to dexmedetomidine
- Language barrier
- Emergency surgery
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648959
|Toronto Western Hospital,UHN.
|Toronto, Ontario, Canada, M5T2S8 |
|Contact: Lashmi kumar venkatraghavan, MD 416-603 ext 5800 Lashmi.Venkatraghavan@uhn.ca |
|Contact: Pirjo Manninen, MD 416-603 ext 5118 Pirjo.Manninen@uhn.ca |
|Sub-Investigator: Ramamani Mariappan, MD |
|Sub-Investigator: Taufik Valiante, MD,PhD |
|Sub-Investigator: Pirjo Manninen, MD |
|Principal Investigator: Lashmikumar Venkatraghavan, MD |
University Health Network, Toronto
||lashmikumar venkatraghavan, MD
||Assistant professor,Toronto western hospital,university health network (UHN)
No publications provided
||University Health Network, Toronto
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 13, 2012
||July 23, 2012
||Canada:University Health Network, Toronto.ON.
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 20, 2014
Adrenergic alpha-2 Receptor Agonists
Central Nervous System Agents
Central Nervous System Depressants
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents